Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke

Trial Profile

Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms TREASURE
  • Sponsors Healios
  • Most Recent Events

    • 11 Oct 2017 Status changed from not yet recruiting to recruiting, according to an Athersys media release.
    • 20 Mar 2017 According to an Athersys media release, this trial has received a priority review designation, enabling acceleration of the potential assessment time to six months for Japans Pharmaceutical and Medical Devices Agency review
    • 23 Feb 2017 According to an Athersys media release, trial overview will be presented at the International Stroke Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top